Blood cancer early detection study
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks for early signs of blood cancers in people who have them or are at higher risk, like family members or older adults. It aims to find cancer sooner, which may lead to better outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a blood cancer such as multiple myeloma, lymphoma, leukemia, or a related condition, OR you have a family member with one, OR you are 65 or older.
- You have not had another cancer (except certain skin cancers) in the past 2 years.
- You do not have HIV, active hepatitis, or an autoimmune disease requiring immune-suppressing treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how T-cells (a type of immune cell) work in people with certain blood cancers (B-cell lymphoma or multiple myeloma) compared to healthy volunteers. The goal is to learn more about the immune system in these cancers, which may help improve future treatments.
This study follows people who may have early, unclear blood count problems or certain genetic/immune patterns that can later lead to bone marrow failure or blood cancers. It may help doctors better understand risks over time and guide earlier care.
This study looks at gene patterns in people with blood cancers to better understand the disease and find possible treatments. If you are being tested for a blood cancer or have a blood cancer that came back or got worse, you may be able to join.
This study is testing a new blood test to help doctors find cancer earlier. If you are 45 or older and have symptoms that might be cancer, or were recently diagnosed with cancer, you may be able to join.
This study collects blood and bone marrow samples from patients with blood cancers to understand why treatments stop working. It aims to improve future treatments.
This study follows adults who have certain blood-cell DNA changes (CHIP or CCUS) to learn how their condition may progress over time. It mainly looks at natural history—what happens in the blood without giving an active treatment.
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.